<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VINORELBINE- vinorelbine injection, solution </strong><br>Actavis Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use vinorelbine injection safely and effectively. See full prescribing information for vinorelbine injection. <br><br></span><span class="Bold">VINORELBINE injection, USP, for intravenous use<br></span><span class="Bold">Initial U.S. Approval: 1994 </span>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"> See full prescribing information for complete boxed warning.</span></span></h1>
<ul class="Disk">
<li>
<span class="Bold"> Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur (</span><span class="Bold"><a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">5.1</a></span><span class="Bold">).</span>
</li>
<li>
<span class="Bold"> Decrease the dose or withhold vinorelbine</span><span class="Bold">in accord with recommended dose modifications (</span><span class="Bold"><a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">2.2</a></span><span class="Bold">). </span>
</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"> See full prescribing information for complete boxed warning.</span></span></h1>
<ul class="Disk">
<li>
<span class="Bold"> Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur (</span><span class="Bold"><a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">5.1</a></span><span class="Bold">).</span>
</li>
<li>
<span class="Bold"> Decrease the dose or withhold vinorelbine</span><span class="Bold">in accord with recommended dose modifications (</span><span class="Bold"><a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">2.2</a></span><span class="Bold">). </span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"> Vinorelbine injection, USP is a vinca alkaloid indicated: </p>
<ul class="Disk">
<li> In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (<a href="#LINK_2752079a-4da1-4daa-940e-821b5c867a69">1</a>) </li>
<li> As a single agent for first-line treatment of patients with metastatic NSCLC (<a href="#LINK_2752079a-4da1-4daa-940e-821b5c867a69">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li> In combination with cisplatin: 25 to 30 mg/m<span class="Sup">2</span> as a single intravenous injection weekly (<a href="#LINK_4cfde80e-5f86-42ca-83c6-8f309f31381d">2.1</a>) </li>
<li> Single agent: 30 mg/m<span class="Sup">2</span> as a single intravenous injection weekly (<a href="#LINK_4cfde80e-5f86-42ca-83c6-8f309f31381d">2.1</a>) </li>
<li> Adjust the dose in patients with decreased neutrophil counts or elevated serum total bilirubin (<a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li>Injection: single use vials of 10 mg/1 mL and 50 mg/5 mL (<a href="#LINK_7228142e-d4cc-46cd-b66a-ebfb9094cd71">3</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> None  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li> Hepatic toxicity: monitor liver function during treatment (<a href="#LINK_6fbf0ef6-8f99-4fef-bf33-8d4909e2044f">5.2</a>) </li>
<li> Severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> including <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and perforation can occur. Institute a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> bowel regimen to mitigate potential <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Monitor for <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (<a href="#LINK_a320b24c-1a8a-404d-b8e5-7154fe9c339a">5.3</a>) </li>
<li> <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> can result in severe tissue injury, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and/or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. Immediately stop vinorelbine and institute recommended management procedures (<a href="#LINK_c3fae52d-26cc-4166-a711-352ecb37a13f">5.4</a>) </li>
<li> Neurologic toxicity: severe sensory and motor neuropathies can occur. Monitor patients for new or worsening signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (<a href="#LINK_d4bddc67-7e84-45dd-aec5-7e9b612c05db">5.5</a>) </li>
<li> Pulmonary toxicity and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> can occur with use of vinorelbine. Monitor patients <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> Interrupt vinorelbine in patients who develop unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (<a href="#LINK_b178c989-f2c6-4620-a1fa-72939bfbf3be">5.6</a>) </li>
<li> Embryo-fetal toxicity: can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus (<a href="#LINK_996c8aaa-7324-40f2-89ad-13a6155a396a">5.7</a>, <a href="#LINK_b64504b4-d63e-49de-a091-b625501f2422">8.1</a>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> Most common adverse reactions (incidence greater than or equal to 20%) are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, liver enzyme elevation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (6.1)   (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-432-8534 or FDA at 1-800-FDA-1088 or <span class="Bold"><span class="Italics">www.fda.gov/medwatch.</span></span></span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li> Inhibitors of CYP3A4: increased severity of adverse reactions (<a href="#LINK_282a1033-2e55-45a9-9653-6388b5ea36bd">7.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk"><li> Nursing Mothers: discontinue drug or nursing taking into consideration importance of drug to mother (<a href="#LINK_7cccbbb8-e2e1-4093-8364-5e1a86a9fe5e">8.3</a>) </li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> 
</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS &amp; USAGE 
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2  DOSAGE &amp; ADMINISTRATION 
</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Recommended Dose 
</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Dose Modifications 
</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 Preparation and Administration
</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Procedures for Proper Handling and Disposal 
</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS </span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS 
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> 
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Hepatic Toxicity
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span> 
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue Injury 
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 Neurologic Toxicity 
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 Pulmonary Toxicity and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span> 
</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 Embryo-Fetal Toxicity 
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS 
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trials Experience </span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Postmarketing Experience 
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS 
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 CYP3A Inhibitors 
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy 
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 Nursing Mothers 
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4 Pediatric Use 
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 Geriatric Use 
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> 
</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.7 Females and Males of Reproductive Potential 
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action 
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.3 Pharmacokinetics 
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  CLINICAL STUDIES 
</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 Combination Use with Cisplatin 
</span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 Single Agent 
</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">15  REFERENCES 
</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING </span></a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17  PATIENT COUNSELIG INFORMATION 
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_b9b31563-b516-4c58-98c5-9bdd0d516fb8"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> 
</span></h1>
<ul class="Disk">
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, hospitalization and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur </span>[see <a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">Warnings and Precautions (5.1)</a>].</li>
<li>
<span class="Bold">Decrease the dose or withhold vinorelbine</span><span class="Bold">in accord with recommended dose modifications </span>[see <a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">Dosage and Administration (2.2)</a>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_2752079a-4da1-4daa-940e-821b5c867a69"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS &amp; USAGE 
</span></h1>
<p class="First">Vinorelbine injection, USP is indicated:</p>
<ul class="Disk">
<li>In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)</li>
<li>As a single agent, for the treatment of patients with metastatic NSCLC</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_59cba7ca-14a6-426a-beaa-1c69b70bdce5"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2  DOSAGE &amp; ADMINISTRATION 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4cfde80e-5f86-42ca-83c6-8f309f31381d"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Recommended Dose 
</span></h2>
<p class="First"><span class="Underline">In Combination with Cisplatin 100 mg/m</span><span class="Underline"><span class="Sup">2</span></span></p>
<ul class="Disk"><li>The recommended dose of vinorelbine is 25 mg/m<span class="Sup">2</span> administered as an intravenous injection or infusion over 6 to 10 minutes on days 1, 8, 15 and 21 of a 28 day cycle in combination with cisplatin 100 mg/m<span class="Sup">2</span> on day 1 only of each 28 day cycle.</li></ul>
<p><span class="Underline">In Combination with Cisplatin 120 mg/m</span><span class="Underline"><span class="Sup">2</span></span></p>
<ul class="Disk">
<li>The recommended dose of vinorelbine is 30 mg/m<span class="Sup">2</span> administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m<span class="Sup">2</span> on days 1 and 29, then every 6 weeks.<p class="First"><span class="Underline">Single-Agent</span></p>
</li>
<li>The recommended dose of vinorelbine is 30 mg/m<span class="Sup">2</span> administered intravenously over 6 to 10 minutes once a week.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d7464764-5186-4643-b7e2-264f87a5bfce"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Dose Modifications 
</span></h2>
<p class="First"><span class="Underline">Hematologic Toxicity</span></p>
<p>[see <a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">Warnings and Precautions (5.1)</a>]</p>
<p>Hold or decrease the dose of vinorelbine in patients with decreased neutrophil counts using the following schema.</p>
<table>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> on Day of Treatment (Cells/mm</span><span class="Bold"><span class="Sup">3</span></span><span class="Bold">)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Percentage of Starting Dose of Vinorelbine</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"> ≥ 1,500</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 100%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1,000 to 1,499</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 50%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> &lt; 1,000</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> Do not administer vinorelbine. Repeat neutrophil count in one week. If three consecutive weekly doses are held because Neutrophil count is &lt; 1,000 cells/mm<span class="Sup">3</span>, discontinue vinorelbine</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> Note : For patients who experience <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> while neutrophil count is &lt; 1,500 or had 2 consecutive weekly doses held due to <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, subsequent doses of vinorelbine should be:</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> &gt; 1,500</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 75%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1,000 to 1,499</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 37.5%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top"> &lt; 1,000</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> Do not administer vinorelbine. </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> Repeat neutrophil count in one week.</td>
</tr>
</tbody>
</table>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>/Toxicity</span></p>
<p>[see <a href="#LINK_6fbf0ef6-8f99-4fef-bf33-8d4909e2044f">Warnings and Precautions (5.2)</a> and <a href="#LINK_189a3e9a-97a9-4c0e-b742-a70853a1c047">Use in Specific Populations (8.6)</a>]</p>
<p>Reduce vinorelbine dose in patients with elevated serum total bilirubin concentration according to the following schema:</p>
<table>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"> <span class="Bold">Serum total bilirubin concentration (mg/dl)</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">Percentage of Starting Dose of Vinorelbine</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> ≤ 2.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 100%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2.1 to 3.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 50%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> &gt; 3.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 25%</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Concurrent Hematologic Toxicity and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In patients with both hematologic toxicity and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, administer the lower of the doses based on the corresponding starting dose of vinorelbine determined from the above schemas.</p>
<p><span class="Underline">Neurologic Toxicity</span></p>
<p>[see <a href="#LINK_d4bddc67-7e84-45dd-aec5-7e9b612c05db">Warnings and Precautions (5.5)</a>]</p>
<p>Discontinue vinorelbine for NCI CTCAE Grade 2 or higher <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span> causing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ed448880-f42d-4eb2-bf7c-404b0f9a7ab1"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 Preparation and Administration
</span></h2>
<p class="First">Preparation of Vinorelbine Injection, USP</p>
<p>Dilute Vinorelbine Injection, USP in either a syringe or intravenous bag using one of the recommended solutions.</p>
<p><span class="Underline">Syringe</span></p>
<p>Dilute to a concentration between 1.5 and 3 mg/mL. The following solutions may be used for dilution:</p>
<ul class="Disk">
<li>5% Dextrose Injection, USP</li>
<li>0.9% Sodium Chloride Injection, USP</li>
</ul>
<p><span class="Underline">Intravenous Bag</span></p>
<p>Dilute to a concentration between 0.5 and 2 mg/mL. The following solutions may be used for dilution:</p>
<ul class="Disk">
<li>5% Dextrose Injection, USP</li>
<li>0.9% Sodium Chloride Injection, USP</li>
<li>0.45% Sodium Chloride Injection, USP</li>
<li>5% Dextrose and 0.45% Sodium Chloride Injection, USP</li>
<li>Ringer's Injection, USP</li>
<li>Lactated Ringer's Injection, USP</li>
</ul>
<p><span class="Underline">Stability</span></p>
<p>Diluted Vinorelbine Injection, USP may be used for up to 24 hours under normal room light when stored in polypropylene syringes or polyvinyl chloride bags at 5° to 30°C (41° to 86°F).</p>
<p><span class="Underline">Administration</span></p>
<p>Administer diluted Vinorelbine Injection, USP over 6 to 10 minutes into the side port of a free-flowing intravenous line followed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> with at least 75 to 125 mL of one of the solutions.</p>
<p>Vinorelbine Injection, USP must only be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any vinorelbine is injected.</p>
<p>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If particulate matter is seen, Vinorelbine Injection, USP should not be administered.</p>
<p><span class="Underline">Management of Suspected <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></span></p>
<ul class="Disk"><li>If vinorelbine leakage into surrounding tissue occurs or is suspected, immediately stop administration of vinorelbine and initiate appropriate management measures in accordance with institutional policies. [see <a href="#LINK_c3fae52d-26cc-4166-a711-352ecb37a13f">Warnings and Precautions (5.4)</a>.]</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a25019a8-f098-49ee-aa88-4889df49f3a9"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Procedures for Proper Handling and Disposal 
</span></h2>
<p class="First">Handle and dispose Vinorelbine Injection, USP consistent with recommendations for the handling and disposal of hazardous drugs<span class="Sup">1</span>.</p>
<p>Exercise caution in handling and preparing the solution of Vinorelbine Injection, USP. The use of gloves is recommended. If the solution of Vinorelbine Injection, USP contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water.</p>
<p>Avoid contamination of the eye with Vinorelbine Injection, USP. If exposure occurs, flush the eyes with water immediately and thoroughly.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_7228142e-d4cc-46cd-b66a-ebfb9094cd71"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS </span></h1>
<p class="First"> Vinorelbine Injection, USP</p>
<p>Clear colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution in single use vials:</p>
<p>1 mL (10 mg/1 mL)</p>
<p>5 mL (50 mg/5 mL)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f5d01bc4-1983-4307-82ac-302fd41b28d1"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS 
</span></h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_3b62a084-0062-4d13-96eb-b347956afbb5"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> 
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> manifested by <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> occur with vinorelbine as a single agent and in combination with cisplatin [see <a href="#LINK_7e7e285f-4c37-4f32-8a65-cd8e370164fd">Adverse Reactions (6.1</a> and <a href="#LINK_0a8d7fff-09c7-4061-b6d3-0e7797c84e50">6.2)</a>]. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> is the major dose-limiting toxicity with vinorelbine. Grade 3-4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 53% of patients treated with vinorelbine at 30 mg/m<span class="Sup">2</span> per week. Dose adjustment due to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurred in 51% of patients (Study 2). In clinical trials with vinorelbine administered at 30 mg/m<span class="Sup">2</span> per week, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> resulted in hospitalizations for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and/or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> in 8% of patients. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> occurred in 1% of patients. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> nadirs occur between 7 and 10 days after dosing with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> count recovery usually occurring within the following 7 to 14 days.</p>
<p>Monitor complete blood counts prior to each dose of vinorelbine. Do not administer vinorelbine to patients with neutrophil counts less than 1,000 cells/mm<span class="Sup">3</span>. Adjustments in the dosage of vinorelbine should be based on neutrophil counts obtained on the day of treatment [see <a href="#LINK_0a8d7fff-09c7-4061-b6d3-0e7797c84e50">Dosage and Administration (2.2)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6fbf0ef6-8f99-4fef-bf33-8d4909e2044f"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Hepatic Toxicity
</span></h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> manifest by elevations of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> and bilirubin can occur in patients receiving vinorelbine alone or in combination with cytotoxic agents. Assess hepatic function prior to initiation of vinorelbine and periodically during treatment. Reduce the dose of vinorelbine for patients who develop elevations in total bilirubin greater than 2 times upper limit of normal [see <a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">Dosage and Administration (2.2)</a> and <a href="#LINK_36c351d5-eaed-422b-b5c5-5f3c0d6b570b">Use in Specific Populations (8.5)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a320b24c-1a8a-404d-b8e5-7154fe9c339a"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span> 
</span></h2>
<p class="First">Severe and fatal <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and perforation occur with vinorelbine administration. Institute a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> bowel regimen to mitigate potential <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> and/or <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, considering adequate dietary fiber intake, hydration, and routine use of stool softeners.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c3fae52d-26cc-4166-a711-352ecb37a13f"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue Injury 
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of vinorelbine can result in severe irritation, local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and/or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occur, immediately stop administration of vinorelbine and institute recommended management procedures. [see <a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">Dosage and Administration (2.2)</a> and <a href="#LINK_7e7e285f-4c37-4f32-8a65-cd8e370164fd">Adverse Reaction (6.1)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d4bddc67-7e84-45dd-aec5-7e9b612c05db"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 Neurologic Toxicity 
</span></h2>
<p class="First">Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine. Monitor patients for new or worsening signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span> and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> while receiving vinorelbine. Discontinue vinorelbine for NCI CTCAE Grade 2 or greater <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> [see <a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">Dosage and Administration (2.2)</a> and <a href="#LINK_7e7e285f-4c37-4f32-8a65-cd8e370164fd">Adverse Reaction (6.1)</a>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b178c989-f2c6-4620-a1fa-72939bfbf3be"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 Pulmonary Toxicity and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span> 
</span></h2>
<p class="First">Pulmonary toxicity, including severe acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>) occurs with use of vinorelbine. <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span> included fatalities. The mean time to onset of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span> after vinorelbine administration was one week (range 3 to 8 days) [see <a href="#LINK_7e7e285f-4c37-4f32-8a65-cd8e370164fd">Adverse Reactions (6.1)</a>].</p>
<p>Interrupt vinorelbine in patients who develop unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or have any evidence of pulmonary toxicity. Permanently discontinue vinorelbine for confirmed <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> or <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_996c8aaa-7324-40f2-89ad-13a6155a396a"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 Embryo-Fetal Toxicity 
</span></h2>
<p class="First">Vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential to use highly effective contraception during therapy with vinorelbine [see <a href="#LINK_b64504b4-d63e-49de-a091-b625501f2422">Use in Specific Populations (8.1</a>, <a href="#LINK_cf34b576-af9b-4037-ba4f-8b66d4308fc9">8.7)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_8004310d-2991-4f68-a144-c292534eb9b9"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS 
</span></h1>
<p class="First">The following serious adverse reactions, which may include fatalities, are discussed in greater detail in other sections of the label:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> [see <a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">Warnings and Precautions (5.1)</a>]</li>
<li>Pulmonary Toxicity and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span> [see <a href="#LINK_6fbf0ef6-8f99-4fef-bf33-8d4909e2044f">Warnings and Precautions (5.2)</a>]</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel Obstruction</span> [see <a href="#LINK_a320b24c-1a8a-404d-b8e5-7154fe9c339a">Warnings and Precautions (5.3)</a>]</li>
<li><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> Tissue Injury [see <a href="#LINK_c3fae52d-26cc-4166-a711-352ecb37a13f">Warnings and Precautions (5.4)</a>]</li>
<li>Neurologic Toxicity [see <a href="#LINK_d4bddc67-7e84-45dd-aec5-7e9b612c05db">Warnings and Precautions (5.5)</a>]</li>
<li>Hepatic Toxicity [see <a href="#LINK_b178c989-f2c6-4620-a1fa-72939bfbf3be">Warnings and Precautions (5.6)</a>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7e7e285f-4c37-4f32-8a65-cd8e370164fd"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trials Experience </span></h2>
<p class="First">Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.</p>
<p><span class="Underline">Single Agent</span></p>
<p>The data below reflect exposure to vinorelbine as a single agent administered at a dose of 30 mg/m<span class="Sup">2</span> on a weekly basis to 365 patients enrolled in 3 controlled studies for metastatic NSCLC and advanced breast cancer. The population included 143 previously untreated metastatic NSCLC patients (Study 3) who received a median of 8 doses of vinorelbine. The patients were aged 32 to 79 (median 61 years), 71% were male, 91% Caucasian, 48% had adenocarcinoma histology. The data also reflect exposure to vinorelbine in 222 patients with previously treated advanced breast cancer who received a median of 10 doses of vinorelbine. Vinorelbine is not indicated for the treatment of breast cancer.</p>
<p>Selected adverse reactions reported in these studies are provided in Tables 1 and 2. The most common adverse reactions (greater than or equal to 20%) of single agent vinorelbine were <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> (AST) elevation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. The most common (greater than or equal to 5%) Grade 3 or 4 adverse reactions were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, increased total bilirubin, AST elevation, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Approximately 49% of NSCLC patients treated with vinorelbine experienced at least one dose reduction due to an adverse reaction. Thirteen percent of patients discontinued vinorelbine due to adverse reactions. The most frequent adverse reactions leading to vinorelbine discontinuation were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<table>
<caption><span>Table 1: Hematologic Adverse Reactions Experienced in Greater Than 5% of Patients Receiving Vinorelbine *†:</span></caption>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" colspan="2" valign="top"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">All patients</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">NSCLC</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" colspan="2" valign="top"> </td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">(n=365)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">(n= 143)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="4">  *Grade based on modified criteria from the National Cancer Institute version 1.  </td></tr>
<tr class="Last"><td colspan="4">  †Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" valign="top"> <span class="Bold">Laboratory </span>
</td>
<td class="Rrule Toprule" valign="top"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> </td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="Bold">Hematologic </span>
</td>
<td class="Rrule" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="bottom"> </td>
<td class="Lrule Rrule" align="center" valign="bottom"> </td>
</tr>
<tr>
<td class="Lrule" valign="top"> </td>
<td class="Rrule" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="bottom"> </td>
<td class="Lrule Rrule" align="center" valign="bottom"> </td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </td>
<td class="Rrule" valign="top"> &lt; 2,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 90%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 80%</td>
</tr>
<tr>
<td class="Lrule" valign="top"> </td>
<td class="Rrule" valign="top"> &lt; 500 cells/mm<span class="Sup">3</span>
</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 36%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 29%</td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </td>
<td class="Rrule" valign="top"> &lt; 4,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 92%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 81%</td>
</tr>
<tr>
<td class="Lrule" valign="top"> </td>
<td class="Rrule" valign="top"> &lt; 1,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 15%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 12%</td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td class="Rrule" valign="top"> &lt; 100,000 cells/mm<span class="Sup">3</span>
</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 5%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 4%</td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anaemia</span> </td>
<td class="Rrule" valign="top"> &lt; 11 g/dl</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 83%</td>
<td class="Lrule Rrule" align="center" valign="bottom"> 77%</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"> </td>
<td class="Botrule Rrule" valign="top"> &lt; 8 g/dl</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"> 9%</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"> 1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" colspan="2"> Hospitalizations due to neutropenic complications </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8%</td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 2: Non-hematologic Adverse Reactions Experienced in Greater Than or Equal to 5% of Patients Receiving Vinorelbine *†:</span></caption>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Lrule Toprule" valign="top"> </td>
<td class="Toprule" align="center" colspan="2" valign="top"> <span class="Bold">All grades</span>
</td>
<td class="Rrule Toprule" align="center" colspan="2" valign="top"> <span class="Bold">Grades 3+4</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">All Patients</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">NSCLC</span>
</td>
<td class="Botrule" align="center" valign="top"> <span class="Bold">All Patients</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> <span class="Bold">NSCLC</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="5" valign="top">  * Grade based on modified criteria from the National Cancer Institute version 1. </td></tr>
<tr><td colspan="5" valign="top">  ‡ Incidence of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> plus <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>. </td></tr>
<tr class="Last"><td colspan="5" valign="top">  †Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" valign="top"> <span class="Bold">Laboratory</span>
</td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="Bold">  Hepatic</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td class="Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" valign="top">     AST increased (n=346)</td>
<td align="center" valign="top"> 67%</td>
<td align="center" valign="top"> 54%</td>
<td align="center" valign="top"> 6%</td>
<td class="Rrule" align="center" valign="top"> 3%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     bilirubin increased</td>
<td align="center" valign="top"> 13%</td>
<td align="center" valign="top"> 9%</td>
<td align="center" valign="top"> 7%</td>
<td class="Rrule" align="center" valign="top"> 5%</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top">     (n=351)</td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Toprule" valign="top"> </td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Toprule" align="center" valign="top"> </td>
<td class="Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" valign="top"> <span class="Bold">Clinical</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td class="Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" valign="top"> 44%</td>
<td align="center" valign="top"> 34%</td>
<td align="center" valign="top"> 2%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td align="center" valign="top"> 36%</td>
<td align="center" valign="top"> 27%</td>
<td align="center" valign="top"> 7%</td>
<td class="Rrule" align="center" valign="top"> 5%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center" valign="top"> 35%</td>
<td align="center" valign="top"> 29%</td>
<td align="center" valign="top"> 3%</td>
<td class="Rrule" align="center" valign="top"> 2%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> </td>
<td align="center" valign="top"> 28%</td>
<td align="center" valign="top"> 38%</td>
<td align="center" valign="top"> 2%</td>
<td class="Rrule" align="center" valign="top"> 5%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span> </td>
<td align="center" valign="top"> 16%</td>
<td align="center" valign="top"> 13%</td>
<td align="center" valign="top"> 2%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> peripheral‡ </td>
<td align="center" valign="top"> 25%</td>
<td align="center" valign="top"> 20%</td>
<td align="center" valign="top"> &lt;2%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top"> 20%</td>
<td align="center" valign="top"> 15%</td>
<td align="center" valign="top"> 2%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" valign="top"> 17%</td>
<td align="center" valign="top"> 13%</td>
<td align="center" valign="top"> 1%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </td>
<td align="center" valign="top"> 12%</td>
<td align="center" valign="top"> 12%</td>
<td align="center" valign="top"> ≤1%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr>
<td class="Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> </td>
<td align="center" valign="top"> 7%</td>
<td align="center" valign="top"> 10%</td>
<td align="center" valign="top"> &lt;1%</td>
<td class="Rrule" align="center" valign="top"> 1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top">     <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </td>
<td class="Botrule" align="center" valign="top"> 7%</td>
<td class="Botrule" align="center" valign="top"> 3%</td>
<td class="Botrule" align="center" valign="top"> 3%</td>
<td class="Botrule Rrule" align="center" valign="top"> 2%</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span> In clinical trials, Grade 3-4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> occurred in 69%, 9% and 1%, respectively of patients receiving single-agent vinorelbine. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> is the major dose-limiting toxicity.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>:</span> <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> was most commonly manifested as <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, hypersthesia, and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>. Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> was observed in 1% of the patients receiving single-agent vinorelbine.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>, including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site, and vein discoloration, occurred in approximately one third of patients; 5% were severe. <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> (<span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">chemical phlebitis</span>) along the vein proximal to the site of injection was reported in 10% of patients.</p>
<p><span class="Italics">Cardiovascular toxicity:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> occurred in 5% of patients; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> occurred in less than 0.1% of patients.</p>
<p><span class="Italics">Pulmonary Toxicity and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory Failure</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> (<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) was reported in 3% of patients; it was severe in 2%. Interstitial pulmonary changes were documented.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> and the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH secretion</span> were each reported in less than 1% of patients.</p>
<p><span class="Underline">In Combination with Cisplatin</span></p>
<p>Table 3 presents the incidence of selected adverse reactions, occurring in greater than or equal to 10% of vinorelbine treated patients reported in a randomized trial comparing the combination of vinorelbine 25 mg/m<span class="Sup">2</span> administered every week of each 28-day cycle and cisplatin 100 mg/m<span class="Sup">2</span> administered on day 1 of each 28-day cycle versus cisplatin alone at the same dose and schedule in patients with previously untreated NSCLC (Study 1).</p>
<table>
<caption><span>Table 3: Adverse Reactions Experienced by Greater Than or Equal to 10% of Patients on Vinorelbineplus Cisplatin versus Single-Agent Cisplatin*</span></caption>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Toprule"></td>
<td>
<span class="Bold">Vinorelbine 25mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold"> plus</span>
</td>
<td class="Toprule" align="center" colspan="2">
<span class="Bold">Cisplatin 100mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold"> (n=210)</span>
</td>
</tr>
<tr>
<td></td>
<td>
<span class="Bold">Cisplatin 100 mg/m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold"> (n=212)</span>
</td>
<td align="center" colspan="2"></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td><span class="Bold">All Grades</span></td>
<td class="Botrule" align="center"><span class="Bold">Grades 3+4</span></td>
<td class="Botrule" align="center"><span class="Bold">All Grades</span></td>
<td class="Botrule" align="center"><span class="Bold">Grades 3+4</span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="5">*Graded according to the standard SWOG criteria version 1. </td></tr>
<tr class="Last"><td colspan="5">*Categorical toxicity grade not specified </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule"><span class="Bold">Laboratory</span></td>
<td class="Toprule" align="center"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Lrule"><span class="Bold">Hematologic</span></td>
<td align="center"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </td>
<td align="center">89%</td>
<td align="center">82%</td>
<td align="center">26%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td align="center">89%</td>
<td align="center">24%</td>
<td align="center">72%</td>
<td class="Rrule" align="center">&lt;8%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </td>
<td align="center">88%</td>
<td align="center">58%</td>
<td align="center">31%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td align="center">29%</td>
<td align="center">5%</td>
<td align="center">21%</td>
<td class="Rrule" align="center">&lt;2%</td>
</tr>
<tr>
<td class="Botrule Lrule"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> </td>
<td class="Botrule" align="center">N/A*</td>
<td class="Botrule" align="center">11%</td>
<td class="Botrule" align="center">N/A*</td>
<td class="Botrule Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Renal</span></td>
<td class="Toprule" align="center"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule">Blood creatinine increased </td>
<td class="Botrule" align="center">37%</td>
<td class="Botrule" align="center">4%</td>
<td class="Botrule" align="center">28%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Lrule Toprule"><span class="Bold">Clinical</span></td>
<td class="Toprule" align="center"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> </td>
<td align="center">67%</td>
<td align="center">12%</td>
<td align="center">49%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center">60%</td>
<td align="center">13%</td>
<td align="center">60%</td>
<td class="Rrule" align="center">14%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center">58%</td>
<td align="center">14%</td>
<td align="center">57%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> </td>
<td align="center">46%</td>
<td align="center">0%</td>
<td align="center">37%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td align="center">35%</td>
<td align="center">3%</td>
<td align="center">16%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </td>
<td align="center">34%</td>
<td align="center">0%</td>
<td align="center">14%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span> </td>
<td align="center">34%</td>
<td align="center">1%</td>
<td align="center">21%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> without <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </td>
<td align="center">20%</td>
<td align="center">2%</td>
<td align="center">4%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing impaired</span> </td>
<td align="center">18%</td>
<td align="center">4%</td>
<td align="center">18%</td>
<td class="Rrule" align="center">&lt;4%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> </td>
<td align="center">17%</td>
<td align="center">&lt;1%</td>
<td align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center">17%</td>
<td align="center">&lt;3%</td>
<td align="center">11%</td>
<td class="Rrule" align="center">&lt;2%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span> </td>
<td align="center">17%</td>
<td align="center">&lt;1%</td>
<td align="center">10%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste alterations</span> </td>
<td align="center">17%</td>
<td align="center">0%</td>
<td align="center">15%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule">Peripheral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> </td>
<td align="center">11%</td>
<td align="center">2%</td>
<td align="center">7%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td align="center">12%</td>
<td align="center">&lt;1%</td>
<td align="center">3%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>/<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>/<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> </td>
<td align="center">10%</td>
<td align="center">3%</td>
<td align="center">&lt;1%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> </td>
<td align="center">12%</td>
<td align="center">&lt;3%</td>
<td align="center">7%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td align="center">11%</td>
<td align="center">&lt;6%</td>
<td align="center">&lt;1%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infection</span> </td>
<td class="Botrule" align="center">10%</td>
<td class="Botrule" align="center">&lt;5%</td>
<td class="Botrule" align="center">3%</td>
<td class="Botrule Rrule" align="center">3%</td>
</tr>
</tbody>
</table>
<p>Patients randomized to vinorelbine plus cisplatin received a median of 3 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. Thirty-Five percent of the eligible patients in the combination arm required treatment discontinuation due to an adverse reaction compared to 19% in the cisplatin alone arm. The incidence of Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was significantly higher in the vinorelbine plus cisplatin arm (82%) compared to the cisplatin alone arm (5%). Four patients in the vinorelbine plus cisplatin arm died of <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span>. Seven additional <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported in the combination arm: 2 from <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>, 1 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, 1 multisystem failure due to an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of vinorelbine, and 3 from <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>.</p>
<p>Table 4 presents the incidence of selected adverse reactions, occurring in greater than or equal to 10% of vinorelbine treated patients reported in a randomized trial of vinorelbine plus cisplatin, vindesine plus cisplatin and vinorelbine alone in patients with stage III or IV NSCLC who had not received prior chemotherapy. A total of 604 patients received either vinorelbine 30 mg/m<span class="Sup">2</span> every week plus cisplatin 120 mg/m<span class="Sup">2</span> on Day 1 and Day 29, then every 6 weeks thereafter (N=207), vindesine 3 mg/m<span class="Sup">2</span> for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m<span class="Sup">2</span> on Days 1 and Day 29, then every 6 weeks thereafter (N=193) or vinorelbine 30mg/m<span class="Sup">2</span> every week (N=204).</p>
<p>Patients randomized to vinorelbine plus cisplatin received a median of 15 weeks of treatment, vindesine plus cisplatin 12 weeks and vinorelbine received 13 weeks. Study discontinuation due to an adverse reaction was required in 27, 22 and 10% of the patients randomized to vinorelbine plus cisplatin, vindesine plus cisplatin and cisplatin alone arms, respectively. Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was significantly greater in the vinorelbine plus cisplatin arm (78%) compared to vindesine plus cisplatin (48%) and vinorelbine alone (53%). <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>, including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was reported in 44% (Grades 3-4, 7%) of the patients receiving vinorelbine plus cisplatin, 58% (Grades 3-4, 17%) of the patients receiving vindesine and cisplatin and 44% (Grades 3-4, 8.5%) of the patients receiving vinorelbine alone.</p>
<table>
<caption><span>Table 4: Adverse Reactions Experienced by Greater Than or Equal to 10 % of Patients from a Comparative Trial of Vinorelbine Plus Cisplatin versus Vindesine Plus Cisplatin versus Single-Agent Vinorelbine *</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">  Vinorelbine /Cisplatin†</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">  Vindesine/Cisplatin‡</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">  Vinorelbine §</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  All Grades</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  Grades 3+4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  All Grades</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  Grades 3+4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  All Grades</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  Grades 3+4</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="7" valign="top">  * Grade based on criteria from the World Health Organization (WHO).  </td></tr>
<tr><td colspan="7" valign="top">  † n=194 to 207; all patients receiving vinorelbine/cisplatin with laboratory and non-laboratory data.  </td></tr>
<tr><td colspan="7" valign="top">  ‡ n=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data.  </td></tr>
<tr><td colspan="7" valign="top">  § n=165 to 201; all patients receiving vinorelbine with laboratory and non-laboratory data.  </td></tr>
<tr><td colspan="7" valign="top">  ¦ Categorical toxicity grade not specified.  </td></tr>
<tr class="Last"><td colspan="7" valign="top">  ¶ <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> includes <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.  </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Laboratory </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">  Hematologic </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 95%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 78%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 79%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 48%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 85%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 53%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 94%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 57%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 82%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 27%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 83%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 32%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 15%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 10%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 3.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">  Renal</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     Blood creatinine </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 46%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> N/A</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 37%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> N/A</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 13%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> N/A</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     increased ¦ </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Clinical</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 74%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 30%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 72%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 25%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 31%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 51%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 56%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 14%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 30%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> ¶ </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 44%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 58%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 17%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 44%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 8.5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 25%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 24%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 12%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     Injection site </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 17%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 22%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">     reaction </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">     <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 10%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 14%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0a8d7fff-09c7-4061-b6d3-0e7797c84e50"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Postmarketing Experience 
</span></h2>
<p class="First">The following adverse reactions have been identified during post-approval use of vinorelbine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> loss of deep tendon reflexes, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Italics">Ear and labyrinth disorders:</span> <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">vestibular disorder</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing impaired</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorders</span>:</span> generalized cutaneous reactions (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>)</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Italics">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="4318391" conceptname="Injection site dermatitis">injection site rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing of skin</span></p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications:</span> radiation <span class="product-label-link" type="condition" conceptid="4033685" conceptname="Radiation recall syndrome">recall phenomenon</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></p>
<p><span class="Italics">Laboratory abnormalities:</span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> including <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></p>
<p><span class="Italics">Other:</span> tumor <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_1bcff30c-aeb7-4d31-84ee-ab212a620b3c"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_282a1033-2e55-45a9-9653-6388b5ea36bd"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 CYP3A Inhibitors 
</span></h2>
<p class="First">Exercise caution in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily. Concurrent administration of vinorelbine with an inhibitor of this metabolic pathway may cause an earlier onset and/or an increased severity of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_b48a68e3-434e-4788-a3fe-b6965ccc1b2e"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b64504b4-d63e-49de-a091-b625501f2422"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy 
</span></h2>
<p class="First"><span class="Underline">Teratogenic Effects: Pregnancy Category D</span></p>
<p><span class="Italics">Risk Summary </span></p>
<p>Vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.</p>
<p><span class="Italics">Animal Data</span></p>
<p>In a mouse embryofetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m<span class="Sup">2</span> or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. Vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m<span class="Sup">2</span> (approximately 0.18 times the recommended human dose based on body surface area) or greater. At doses that did not cause maternal toxicity in either species, vinorelbine administration resulted in reduced fetal weight and delayed ossification.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7cccbbb8-e2e1-4093-8364-5e1a86a9fe5e"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers 
</span></h2>
<p class="First">It is not known whether this drug is present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from vinorelbine, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4ff3d3e8-2885-4f2f-af53-13c0e639a0a6"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use 
</span></h2>
<p class="First">The safety and effectiveness of vinorelbine in pediatric patients have not been established. Results from a single-arm study of vinorelbine administered at the dose of 33.75 mg/m<span class="Sup">2</span> (for 35 patients) or at the dose of 30mg/m<span class="Sup">2</span> (for 11 patients) every week during 6 weeks followed by 2 weeks of rest was evaluated (courses of 8 weeks). Forty-six patients age 1 to 25 (median 11 years) with recurrent solid <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>, including <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span> or undifferentiated <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> (N=21 patients), <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span> (N= 4 patients), and central nervous system (CNS) tumors (N=21 patients) were enrolled. The most significant grade 3 or 4 hematological adverse reactions were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (70%) and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (33%). The most significant grade 3 or 4 non-hematological toxicity adverse reactions were motor (15%) or cranial (13%) <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> (13%) and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (11%). Objective tumor response was observed in 2 out of 21 patients with <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span> or undifferentiated <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>. No objective tumor response was observed in patients with CNS tumors (N=21) or <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span> (N=4).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_36c351d5-eaed-422b-b5c5-5f3c0d6b570b"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use 
</span></h2>
<p class="First">Of the 769 number of patients who received vinorelbine alone and vinorelbine in combination with Cisplatin in studies 1, 2 and 3, 247 patients were 65 years of age or older. No overall differences in safety, efficacy and pharmacokinetic parameters were observed between these patients and younger patients. [see <a href="#LINK_57b19a09-cc7f-4702-91d0-198af6efaef4">Clinical Pharmacology (12.3)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_189a3e9a-97a9-4c0e-b742-a70853a1c047"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> 
</span></h2>
<p class="First">The influence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of vinorelbine has not been evaluated, but the liver plays an important role in the metabolism of vinorelbine. Elevations of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> occur in greater than 60% of the patients receiving vinorelbine alone (6% Grade 3-4). Therefore, exercise caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Reduce the dose of vinorelbine for patients with bilirubin elevation [see <a href="#LINK_d7464764-5186-4643-b7e2-264f87a5bfce">Dosage and Administration (2.2)</a> and <a href="#LINK_6fbf0ef6-8f99-4fef-bf33-8d4909e2044f">Warnings and Precautions (5.2)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf34b576-af9b-4037-ba4f-8b66d4308fc9"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.7 Females and Males of Reproductive Potential 
</span></h2>
<p class="First"><span class="Underline">Contraception</span></p>
<p><span class="Italics">Females</span></p>
<p>Vinorelbine can cause fetal harm when administered to a pregnant woman [see <a href="#LINK_b64504b4-d63e-49de-a091-b625501f2422">Use in Specific Populations (8.1)</a>]. Advise female patients of reproductive potential to use highly effective contraception during therapy with vinorelbine.</p>
<p><span class="Italics">Males</span></p>
<p>Vinorelbine may damage spermatozoa [see <a href="#LINK_39ab5882-9a26-40bd-8f0e-42a076cda894">Nonclinical Toxicology (13.1)</a>]. Males with female sexual partners of reproductive potential should use highly effective contraception during and for 3 months after therapy with vinorelbine.</p>
<p><span class="Underline">Fertility</span></p>
<p><span class="Italics">Males </span></p>
<p>Based on animal findings, vinorelbine may cause decreased fertility in males [see <a href="#LINK_39ab5882-9a26-40bd-8f0e-42a076cda894">Nonclinical Toxicology (13.1)</a>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_63c36fff-d2a3-4c11-801c-7696282dd542"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE 
</span></h1>
<p class="First">There is no known antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of vinorelbine. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> involving quantities up to 10 times the recommended dose (30 mg/m<span class="Sup">2</span>) have been reported. The toxicities described were consistent with those listed in the <a href="#LINK_8004310d-2991-4f68-a144-c292534eb9b9">ADVERSE REACTIONS</a> section including <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, and <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. Bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span> have also been reported. Fatalities have occurred following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of vinorelbine. If overdosage occurs, general supportive measures together with appropriate blood transfusions, growth factors, and antibiotics should be instituted as deemed necessary by the physician.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_d0eb60cb-d8bd-4573-810c-07a36aadc247"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION 
</span></h1>
<p class="First">Vinorelbine tartrate, USP is a semi-synthetic vinca alkaloid for intravenous injection. Chemically, vinorelbine tartrate, USP is 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2, 3-dihydroxybutanedioate (1:2)(tartrate)] and has the following structure:</p>
<div class="Figure"><img alt="3c00b60d-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd3dcc9a-e40c-4677-9ee6-f318e7c7d835&amp;name=vinorelbine-injection-usp-sindan-1.jpg"></div>
<p>C<span class="Sub">45</span>H<span class="Sub">54</span>N<span class="Sub">4</span>O<span class="Sub">8</span>(2C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">6 </span>               M.W. 1079.12.</p>
<p>Vinorelbine Injection, USP is a sterile nonpyrogenic aqueous solution. Each milliliter of solution contains 10 mg vinorelbine tartrate, USP in Water for Injection. The pH of Vinorelbine Injection, USP is approximately 3.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_59e08be1-a2d8-46be-a090-e8a994cae53e"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e415745c-517d-4059-a661-18d4b6b28ca6"></a><a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action 
</span></h2>
<p class="First">Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vinorelbine inhibited mitotic microtubule formation in intact mouse embryo tectal plates at a concentration of 2 µM inducing a blockade of cells at metaphase, but produced depolymerization of axonal microtubules at a concentration 40 µM, suggesting a modest selectivity of vinorelbine for mitotic microtubules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_57b19a09-cc7f-4702-91d0-198af6efaef4"></a><a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics 
</span></h2>
<p class="First">The pharmacokinetics of vinorelbine were studied in 49 patients who received doses of 30 mg/m<span class="Sup">2</span> administered as 15-to 20-minute constant-rate infusions. Vinorelbine concentrations in plasma decay in a triphasic manner. The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg.</p>
<p><span class="Underline">Distribution</span></p>
<p>Steady-state volume of distribution (V<span class="Sub">SS</span>) values range from 25.4 to 40.1 L/kg. Vinorelbine demonstrated high binding to human platelets and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The free fraction was approximately 0.11 in human plasma over a concentration range of 234 to 1169 ng/mL. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin, 5-fluorouracil, or doxorubicin.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces. Two metabolites of vinorelbine have been identified in human blood, plasma, and urine; vinorelbine N-oxide and deacetylvinorelbine. Deacetylvinorelbine has been demonstrated to be the primary metabolite of vinorelbine in humans, and has been shown to possess antitumor activity similar to vinorelbine. Therapeutic doses of vinorelbine (30 mg/m<span class="Sup">2</span>) yield very small, if any, quantifiable levels of either metabolite in blood or urine. The metabolism of vinorelbine is mediated by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily.</p>
<p><span class="Underline">Excretion</span></p>
<p>After intravenous administration of radioactive vinorelbine, approximately 18% and 46% of administered radioactivity was recovered in urine and feces, respectively. In a different study, 10.9% ± 0.7% of a 30-mg/m<span class="Sup">2</span> intravenous dose was excreted as parent drug in urine.</p>
<p><span class="Underline">Specific Populations</span></p>
<p>Elderly: Age has no effect on the pharmacokinetics (CL, V<span class="Sub">SS</span> and t<span class="Sub">1/2</span> ) of vinorelbine.</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>The pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_414d26fa-d944-4710-bad9-8cb19717217b"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_39ab5882-9a26-40bd-8f0e-42a076cda894"></a><a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 
</span></h2>
<p class="First">The carcinogenic potential of vinorelbine has not been studied. Vinorelbine has been shown to affect chromosome number and possibly structure <span class="Italics">in vivo</span> (polyploidy in bone marrow cells from Chinese hamsters and a positive micronucleus test in mice). It was not mutagenic in the Ames test and gave inconclusive results in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK Locus assay.</p>
<p>Vinorelbine did not affect fertility to a statistically significant extent when administered to rats on either a once-weekly (9 mg/m<span class="Sup">2</span>, approximately one third the human dose) or alternate-day schedule (4.2 mg/m<span class="Sup">2</span>, approximately 0.14 times the human recommended dose) prior to and during mating. In male rats, administration of vinorelbine twice weekly for 13 or 26 weeks at dose levels of 2.1 and 7.2 mg/m<span class="Sup">2</span> (approximately 0.07 and 0.24 times the recommended human dose), respectively, resulted in decreased spermatogenesis and prostate/seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> secretion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_85edb276-a80b-4916-a0f3-df7cd7cb57ae"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14  CLINICAL STUDIES 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3613a86a-0f39-4425-9de9-a18746f5c04a"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1 Combination Use with Cisplatin 
</span></h2>
<p class="First">The safety and efficacy of vinorelbine in combination with cisplatin was evaluated in two randomized, multicenter trials.</p>
<p><span class="Underline">Cisplatin 100mg/m</span><span class="Underline"><span class="Sup">2</span></span></p>
<p>Study 1 was a randomized, multicenter, open-label trial of vinorelbine plus cisplatin and cisplatin alone for the treatment of stage IV or stage IIIb NSCLC patients with malignant <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> or multiple lesions in more than one lobe of the ipsilateral lung who had not received prior chemotherapy. A total of 432 patients were randomized 1:1 to receive either vinorelbine 25 mg/m<span class="Sup">2</span> on Day 1 then every week of each 28-day cycle with cisplatin 100 mg/m<span class="Sup">2</span> administered on Day 1 of each 28-day cycle (N=214) or cisplatin 100 mg/m<span class="Sup">2</span> on Day 1 of each 28-day cycle (N=218).</p>
<p>Patient demographics and disease characteristics were similar between arms. Of the overall study population, the median age was 64 (range 33 to 84), 66% were male, 80% were Caucasian, 92% had stage IV disease and 8% stage IIIB, 53% had adenocarcinoma, 21% squamous cell, 14% large cell histology. The major efficacy outcome measure was overall survival. The efficacy results are presented in Table 7 and Figure 1.</p>
<table>
<caption><span> Table 7. Efficacy Results (Study 1)</span></caption>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Vinorelbine plus Cisplatin</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Cisplatin Alone</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> </td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">(N=214)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">(N=218)</span>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Overall Survival </span>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"> Median Survival in months </td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 7.8 (6.9, 9.6 )</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> 6.2 (5.4, 7.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> (95% CI) </td>
<td class="Botrule Lrule Rrule" valign="top"> </td>
<td class="Botrule Lrule Rrule" valign="top"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> Unstratified log-rank p-value</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> 0.01</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"> <span class="Bold">Overall Response rate</span> (ORR)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"> Evaluable patients </td>
<td class="Lrule Rrule" align="center" valign="bottom"> N = 206</td>
<td class="Lrule Rrule" align="center" valign="top"> N=209</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> ORR (95% CI) </td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"> 19% (14%, 25%)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> 8% (5%, 13% )</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"> Chi-square test p-value </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> &lt;0.001</td>
</tr>
</tbody>
</table>
<div class="Figure">
<img alt="3c00b60d-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd3dcc9a-e40c-4677-9ee6-f318e7c7d835&amp;name=vinorelbine-injection-usp-sindan-2.jpg"><p class="MultiMediaCaption">Figure 1: Overall Survival Vinorelbine /Cisplatin versus Single-Agent Cisplatin</p>
</div>
<p><span class="Underline">Cisplatin 120mg/m</span><span class="Underline"><span class="Sup">2</span></span></p>
<p>Study 2 was a randomized, 3-arm, open-label, multicenter trial of vinorelbine plus cisplatin, vindesine plus cisplatin and vinorelbine alone for the treatment of patients with stage III or IV NSCLC who had not received prior chemotherapy. The study was conducted in Europe. A total of 612 patients were randomized 1:1:1 to receive vinorelbine 30 mg/m<span class="Sup">2</span> every week of a 6-week cycle plus cisplatin 120 mg/m<span class="Sup">2</span> on Day 1 and Day 29, then every 6 weeks thereafter (N=206); and vindesine 3 mg/m<span class="Sup">2</span> for 6 weeks, then every other week thereafter plus cisplatin 120 mg/m<span class="Sup">2</span> on Days 1 and Day 29, then every 6 weeks thereafter (N=200) or vinorelbine 30mg/m<span class="Sup">2</span> every week of a 6-week cycle (N=206). The main efficacy outcome measure was to compare overall survival between vinorelbine plus cisplatin and vindesine plus cisplatin. The other efficacy outcome measure was to compare overall survival in the better of the two combination regimens to that of vinorelbine alone.</p>
<p>Patient demographics were in general similar between arms: the median age of the overall population was 60 years (range 30 to 75), 90% were male, 78% had WHO performance status of 0 or 1. Tumor characteristics were in general similar with the exception of histologic subtype of NSCLC. Adenocarcinoma was the histologic subtype in 32% of patients in the vinorelbine plus cisplatin arm, 40% of patients in vindesine plus cisplatin arm and 28% of patients on the vinorelbine alone arm. Ten percent of the patients had stage IIIA disease, 28% stage IIIB and 50% stage IV. Twelve percent of the patients had received prior surgery or radiotherapy.</p>
<p>The efficacy results of Study 2 are presented in Table 8.</p>
<table>
<caption><span> Table 8. Efficacy Results (Study 2)</span></caption>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"> </td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Vinorelbine Alone</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Vinorelbine plus</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Vindesine plus</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> </td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">(N=206)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">cisplatin (N=206)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <span class="Bold">cisplatin (N=200)</span>
</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Toprule" colspan="4" valign="top"> <span class="Sup">1</span>n/a = not applicable </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"> <span class="Bold">Median survival in months (99.5% CI) </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7.2 (5.4 to 9.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 9.2 (7.4 to 11.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 7.4 (6.1 to 9.1)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Unstratified log-rank </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n/a<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> 0.087</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> p-value </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> 0.05</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n/a</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" valign="top"> <span class="Bold">Overall Response </span>
</td>
<td class="Lrule Rrule Toprule" align="center"> </td>
<td class="Lrule Rrule Toprule" align="center"> </td>
<td class="Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"> (ORR) </td>
<td class="Lrule Rrule" align="center"> N=205</td>
<td class="Lrule Rrule" align="center"> N=203</td>
<td class="Lrule Rrule" align="center"> N=198</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"> Evaluable Patients </td>
<td class="Lrule Rrule" align="center"> 14% (10%, 20%)</td>
<td class="Lrule Rrule" align="center"> 28% (22%, 35%)</td>
<td class="Lrule Rrule" align="center"> 19% (14%, 25% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">ORR (95% CI) </span>
</td>
<td class="Botrule Lrule Rrule" align="center"> </td>
<td class="Botrule Lrule Rrule" align="center"> </td>
<td class="Botrule Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Chi-square test p-</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> 0.03</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> value </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"> &lt; 0.001</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> n/a</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3c0ace66-61a8-4c14-bf8c-f91d4099ce47"></a><a name="section-13.2"></a><p></p>
<h2><span class="Bold">14.2 Single Agent 
</span></h2>
<p class="First">The safety and efficacy of vinorelbine as a single agent was evaluated in one randomized multi-center trial.</p>
<p>Study 3 was a randomized, open-label clinical trial of vinorelbine or 5-Fluorouracil (5-FU) plus leucovorin (LV) in patients with Stage IV NSCLC who had not received prior chemotherapy A total of 211 patients were randomized 2:1 to receive vinorelbine 30 mg/m<span class="Sup">2</span> weekly of a 8-week cycle (N=143) or 5-FU 425 mg/m<span class="Sup">2</span> bolus intravenously plus LV 20 mg/m<span class="Sup">2</span> bolus intravenously daily for 5 days of a 4-weeks cycle (N=68).</p>
<p>Patient demographics and disease characteristics were in general similar between arms. In the overall population, the median age was 61 years (range 32 to 83), 74% were male, 88% were Caucasian, 46% had adenocarcinoma histology. Fifty percent of the patients had Karnofsky performance status greater than or equal to 90 in the vinorelbine arm compared to 38% in the 5-FU and LV arm.</p>
<p>The primary efficacy outcome of the study was overall survival. The median survival time was 30 weeks versus 22 weeks for patients receiving vinorelbine versus 5-FU/LV, respectively (P=0.06). Partial objective responses were observed in 11.1% (95% CI=6.2%, 17.9%) and 3.5% (95% CI=0.4%, 11.9%) of patients who received vinorelbine and 5-FU/LV, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_7024cab5-545f-4659-b171-843ce5732cff"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">15  REFERENCES 
</span></h1>
<ol class="Arabic"><li>OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_3dec812f-4731-4518-8c7a-88bb9d137397"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING </span></h1>
<p class="First">Vinorelbine Injection, USP is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solution in Water for Injection, containing 10 mg vinorelbine per mL. Vinorelbine Injection, USP is available in single-use, clear glass vials with elastomeric stoppers and red (10 mg/1 mL) and green (50 mg/5 mL) caps, individually packaged in a carton in the following vial sizes:</p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" valign="top"> NDC</td>
<td class="Botrule" valign="top"> Vinorelbine Injection, USP</td>
<td class="Botrule" valign="top"> Package Factor</td>
</tr>
<tr>
<td class="Toprule" valign="top"> 45963-607-55</td>
<td class="Toprule" valign="top"> 10 mg/1 mL Single-Use Vial</td>
<td class="Toprule" valign="top"> 1 vial per carton</td>
</tr>
<tr class="Last">
<td valign="top"> 45963-607-56</td>
<td valign="top"> 50 mg/5 mL Single-Use Vial</td>
<td valign="top"> 1 vial per carton</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Storage Conditions</span></p>
<p>Store the vials under refrigeration at 2° to 8°C (36° to 46°F) in the carton.</p>
<p>Unopened vials of Vinorelbine Injection, USP are stable at 25°C (77°F) for up to 72 hours.</p>
<p><span class="Bold">Protect from light. </span></p>
<p><span class="Bold">DO NOT FREEZE.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p>Vinorelbine Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_09b0731e-d168-498f-8212-28ad29fdf1e1"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELIG INFORMATION 
</span></h1>
<p class="First">Inform patients of the following:</p>
<ul class="Disk">
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></span><p class="First">Advise patients to contact a healthcare provider for new onset <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [see <a href="#LINK_005b5c98-5916-4961-a8b2-c5d57bdcbf20">Warnings and Precautions (5.1)</a>]</p>
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span></span><p class="First">Advise patients to follow a diet rich in fibers, drink fluids to stay well hydrated and use stool softeners to avoid <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Contact a health care provider for severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, new onset <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> [see <a href="#LINK_a320b24c-1a8a-404d-b8e5-7154fe9c339a">Warnings and Precautions (5.3)</a>]</p>
</li>
<li>
<span class="Underline">Neurologic toxicity</span><p class="First">Advise patients to contact a health care provider for new onset or worsening of <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, decrease sensation or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> [see <a href="#LINK_d4bddc67-7e84-45dd-aec5-7e9b612c05db">Warnings and Precautions (5.5)</a>]</p>
</li>
<li>
<span class="Underline">Pulmonary Toxicity</span><p class="First">Advise patients to contact a healthcare provider for new onset or worsening of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> or other new pulmonary symptoms [see <a href="#LINK_b178c989-f2c6-4620-a1fa-72939bfbf3be">Warnings and Precautions (5.6)</a>]</p>
</li>
<li>
<span class="Underline">Females and Males of Reproductive Potential</span><ul class="Circle">
<li>Vinorelbine Injection, USP can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use highly effective contraception during treatment with Vinorelbine Injection, USP, and to contact their healthcare provider if they become pregnant, or if pregnancy is suspected [see <a href="#LINK_996c8aaa-7324-40f2-89ad-13a6155a396a">Warnings and Precautions (5.7)</a> and <a href="#LINK_cf34b576-af9b-4037-ba4f-8b66d4308fc9">Use in Specific Populations (8.7)</a>].</li>
<li>Vinorelbine Injection, USP may damage sperm. Advise males to use highly effective contraception during and for 3 months after therapy [see <a href="#LINK_cf34b576-af9b-4037-ba4f-8b66d4308fc9">Use in Specific Population (8.7)</a> and <a href="#LINK_39ab5882-9a26-40bd-8f0e-42a076cda894">Nonclinical Toxicology (13.1)</a>].</li>
<li>Vinorelbine Injection, USP, may cause decreased fertility in males [see <a href="#LINK_39ab5882-9a26-40bd-8f0e-42a076cda894">Nonclinical Toxicology (13.1)</a>].</li>
</ul>
</li>
</ul>
<p>Manufactured by:</p>
<p>Sindan Pharma SRL</p>
<p>11 Ion Mihalache Blvd</p>
<p>Bucharest 1, Romania 011171</p>
<p>Distributed by:</p>
<p>Actavis Pharma, Inc.</p>
<p>Parsippany, NJ 07054 USA</p>
<p>Revised – June 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_92a1e4d5-1f96-4397-969f-72b4fb3b4536"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL </span></h1>
<div class="Figure"><img alt="1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd3dcc9a-e40c-4677-9ee6-f318e7c7d835&amp;name=vinorelbine-injection-usp-sindan-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VINORELBINE 		
					</strong><br><span class="contentTableReg">vinorelbine injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:45963-607</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VINORELBINE</strong> (VINORELBINE) </td>
<td class="formItem">VINORELBINE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:45963-607-55</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:45963-607-56</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078011</td>
<td class="formItem">01/05/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Pharma, Inc.
							(119723554)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sindan-Pharma Srl</td>
<td class="formItem"></td>
<td class="formItem">683754121</td>
<td class="formItem">ANALYSIS(45963-607), LABEL(45963-607), MANUFACTURE(45963-607), PACK(45963-607)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6c08d181-630c-4f49-9017-a10d0420838f</div>
<div>Set id: dd3dcc9a-e40c-4677-9ee6-f318e7c7d835</div>
<div>Version: 8</div>
<div>Effective Time: 20140625</div>
</div>
</div> <div class="DistributorName">Actavis Pharma, Inc.</div></p>
</body></html>
